250 related articles for article (PubMed ID: 22329458)
1. Sapacitabine for cancer.
Liu X; Kantarjian H; Plunkett W
Expert Opin Investig Drugs; 2012 Apr; 21(4):541-55. PubMed ID: 22329458
[TBL] [Abstract][Full Text] [Related]
2. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
Liu XJ; Nowak B; Wang YQ; Plunkett W
Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
[TBL] [Abstract][Full Text] [Related]
3. TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.
Al Abo M; Sasanuma H; Liu X; Rajapakse VN; Huang SY; Kiselev E; Takeda S; Plunkett W; Pommier Y
Mol Cancer Ther; 2017 Nov; 16(11):2543-2551. PubMed ID: 28802254
[TBL] [Abstract][Full Text] [Related]
4. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
5. Mechanism-Based Drug Combinations with the DNA Strand-Breaking Nucleoside Analog CNDAC.
Liu X; Jiang Y; Nowak B; Hargis S; Plunkett W
Mol Cancer Ther; 2016 Oct; 15(10):2302-2313. PubMed ID: 27474148
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Hanaoka K; Suzuki M; Kobayashi T; Tanzawa F; Tanaka K; Shibayama T; Miura S; Ikeda T; Iwabuchi H; Nakagawa A; Mitsuhashi Y; Hisaoka M; Kaneko M; Tomida A; Wataya Y; Nomura T; Sasaki T; Matsuda A; Tsuruo T; Kurakata S
Int J Cancer; 1999 Jul; 82(2):226-36. PubMed ID: 10389757
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of sapacitabine in treating patients with acute myeloid leukemia.
Czemerska M; Robak T; Wierzbowska A
Expert Opin Pharmacother; 2018 Nov; 19(16):1835-1839. PubMed ID: 30222471
[TBL] [Abstract][Full Text] [Related]
8. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
Liu X; Wang Y; Benaissa S; Matsuda A; Kantarjian H; Estrov Z; Plunkett W
Blood; 2010 Sep; 116(10):1737-46. PubMed ID: 20479284
[TBL] [Abstract][Full Text] [Related]
9. Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.
Liu X; Jiang Y; Nowak B; Qiang B; Cheng N; Chen Y; Plunkett W
Cancer Chemother Pharmacol; 2018 Feb; 81(2):255-267. PubMed ID: 29189915
[TBL] [Abstract][Full Text] [Related]
10. HDAC Inhibition Induces MicroRNA-182, which Targets RAD51 and Impairs HR Repair to Sensitize Cells to Sapacitabine in Acute Myelogenous Leukemia.
Lai TH; Ewald B; Zecevic A; Liu C; Sulda M; Papaioannou D; Garzon R; Blachly JS; Plunkett W; Sampath D
Clin Cancer Res; 2016 Jul; 22(14):3537-49. PubMed ID: 26858310
[TBL] [Abstract][Full Text] [Related]
11. Sapacitabine in the treatment of acute myeloid leukemia.
Norkin M; Richards AI
Expert Rev Anticancer Ther; 2015; 15(11):1261-6. PubMed ID: 26523431
[TBL] [Abstract][Full Text] [Related]
12. Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine.
Liu X; Matsuda A; Plunkett W
Mol Cancer Ther; 2008 Jan; 7(1):133-42. PubMed ID: 18202016
[TBL] [Abstract][Full Text] [Related]
13. Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types.
Green SR; Choudhary AK; Fleming IN
Br J Cancer; 2010 Oct; 103(9):1391-9. PubMed ID: 20924380
[TBL] [Abstract][Full Text] [Related]
14. Improvement of the antitumor activity of poorly soluble sapacitabine (CS-682) by using Soluplus® as a surfactant.
Obata T; Suzuki Y; Ogawa N; Kurimoto I; Yamamoto H; Furuno T; Sasaki T; Tanaka M
Biol Pharm Bull; 2014; 37(5):802-7. PubMed ID: 24790002
[TBL] [Abstract][Full Text] [Related]
15. Repair of 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine-induced DNA single-strand breaks by transcription-coupled nucleotide excision repair.
Wang Y; Liu X; Matsuda A; Plunkett W
Cancer Res; 2008 May; 68(10):3881-9. PubMed ID: 18483273
[TBL] [Abstract][Full Text] [Related]
16. Drug evaluation: sapacitabine--an orally available antimetabolite in the treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2006 Jun; 7(6):565-73. PubMed ID: 16784028
[TBL] [Abstract][Full Text] [Related]
17. Molecular basis for G2 arrest induced by 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine and consequences of checkpoint abrogation.
Liu X; Guo Y; Li Y; Jiang Y; Chubb S; Azuma A; Huang P; Matsuda A; Hittelman W; Plunkett W
Cancer Res; 2005 Aug; 65(15):6874-81. PubMed ID: 16061671
[TBL] [Abstract][Full Text] [Related]
18. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
Muggia F; Diaz I; Peters GJ
Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
[TBL] [Abstract][Full Text] [Related]
19. Nucleosides and nucleotides. 141. Chemical stability of a new antitumor nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine in alkaline medium: formation of 2'-C-cyano-2'-deoxy-1-beta-D-ribo-pentofuranosylcytosine and its antitumor activity.
Azuma A; Hanaoka K; Kurihara A; Kobayashi T; Miyauchi S; Kamo N; Tanaka M; Sasaki T; Matsuda A
J Med Chem; 1995 Aug; 38(17):3391-7. PubMed ID: 7650692
[TBL] [Abstract][Full Text] [Related]
20. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
Azuma A; Huang P; Matsuda A; Plunkett W
Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
